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High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing
incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment deescalation clinical trials challenging. To address the need for noninvasive biomarkers that diﬀerentiate patient outcomes, serum
antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients (n = 48). We
have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to
mortality (p = :004) with 100% speciﬁcity as a predictive test.

1. Introduction
Head and neck cancer (HNC) is estimated to aﬀect over 4
million people worldwide and is the seventh most common
cancer type [1–3]. Human papillomavirus (HPV)-associated
HNC has been on the rise for the last 3 decades and surpassed cervical cancer as the most proliﬁc cause of HPVassociated cancer in the United States [1–3]. Although it is
diagnosed at a median age of 60 years, a recent rise in
HPV-associated HNC has increased the HNC incidence in
younger patients [2, 3].
The most common type of HNC is squamous cell carcinoma (HNSCC). The risk factors for HNSCC include smoking and high-risk HPV [4]. Although smoking prevalence
has been on the decline for the past half century, HPVassociated HNC remains a signiﬁcant threat [4]. 50% of
HNC patients have detectable oncogenic HPV DNA, with
the highest proportion of HPV positivity in non-smokers

[4]. HPV positivity may guide the treatment strategies as
T-cell-speciﬁc therapies have been reported to be more eﬀective in HPV-positive patients [5–7]. Current clinical guidelines for HNC patients outline an initial p16 test with a
follow-up HPV DNA test [8]. However, p16 immunohistochemistry has been widely accepted as a surrogate marker
for HPV essentially replacing HPV in situ hybridization
(ISH) in clinical settings [9]. The reason for this is that
HPV ISH is not done routinely in practice and sometimes
includes low-risk HPV subtypes. Therefore, because of the
availability of p16 data for each patient, this marker was
used to identify HPV-associated cancers in this manuscript.
Although the beneﬁt of identifying p16 status is evident,
there is signiﬁcant heterogeneity within HPV-associated
HNC and patients’ treatment response varies drastically
[10]. There are currently limited molecular tools for diﬀerentiating between treatment responders and treatment
non-responders. Multiple recent clinical trial investigation
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Table 1: E7 antibody trend predicts mortality in head and neck cancer.
Number of patients
(%)

Overall
Lost to follow-up
Patients available for mortality analysis

Mortality

No
mortality

48
5
43

9

34

P -value

Age

<60
≥60

24 (56)
19 (44)

6
3

18
16

.677 (NS)

Sex

Male
Female

37 (86)
6 (14)

7
2

30
4

.589 (NS)

Race

White
African American

41 (95)
2 (5)

8
1

33
1

.378 (NS)

1
2
3
4

1 (2)
3 (7)
6 (14)
33 (77)

1
0
4
4

0
3
2
29

.006(∗∗)

Yes
No (control)

39 (91)
4 (9)

8
1

31
3

1 (NS)

4 (10)

4

0

19 (50)

3

16

16 (40)

1

15

Stage at diagnosis

P16 +

E7 antibody trend among P16 positive
patients

Positive with increasing
trend
Positive with decreasing
trend
Negative

.0007(∗∗∗
)

Contingency tables of patient demographics at the time of diagnosis, stage, HPV relevant markers, and E7 trend are shown to compare HNC patients with
mortality and patients with no mortality. The Fisher’s exact test is used for the 2 × 2 contingency tables, and the Fisher’s exact test with Freeman-Halton
extension is added to the larger contingency table to show the signiﬁcance level of observed diﬀerences (NS = not signiﬁcant, ∗∗ = p ≤ :01, ∗∗∗ = p ≤ :001).

Table 2: E7 antibody trend predicts cancer recurrence or progression to mortality among HPV-associated HNC patients.

p16+ HNC patients

E7 antibody trend among
p16 positive patients

Positive with
increasing trend
Positive with
decreasing trend
Negative

Number of
patients (%)

Cancer recurrence or
progression to mortality

No cancer recurrence or
progression to mortality

39

11

27

4 (10)

4

0

19 (50)

5

14

16 (40)

2

14

P-value

P = :004
(∗∗)

Contingency table of HPV-associated HNC patients’ immune response trend in consecutive clinical visits throughout the treatment. The Fisher’s exact test
with Freeman-Halton extension is used for signiﬁcance testing (∗∗ = p ≤ :01).

de-escalation treatment strategies have failed to meaningfully change clinical practice [10].
Therefore, this study sought to identify molecular markers
for squamous cell head and neck cancer (HNSCC) that can be
used to tailor cancer treatment to individual patient needs.
Our research has been particularly interested in two potential
prognostic markers: oncoproteins E6 and E7, which inactivate
the tumor suppressors p53 and RB, respectively [11]. P16, the
HPV-associated HNC marker used in this paper, is upregulated by E7’s suppression of RB [12, 13].

This presence of E7 in the blood stream when cancer is
active is due to one of the following mechanisms: cancer cells
ﬂoating in the blood are transcriptionally active, tumors,
release oncoproteins directly into tumor vascular beds
because of necrosis, or tumor cells are secreting exosomes
of viral oncoproteins [14–17]. Therefore, measuring antibodies to E7 via liquid biopsy throughout the treatment
course provides a potential marker for predicting cancer
outcome and activity. Here, we aim to further examine the
activity of E7 throughout cancer, the potential of E7
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a noninvasive prognostic marker.
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2. Methods
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Figure 1: Heat map of anti-E7 ELISA values at consecutive clinical
visits for HPV-18 and HPV-16 E7 antibodies. All patients with
increasing trends on ELISA (patients 610, 619, 625, and 864)
correlated with patient mortality. The p16 negative controls
(patients 705, 865, and 872) are all seronegative for anti-E7 as
predicted. Note that HPV-18 and HPV-16 were used to generate
the E7 antigens but are not speciﬁc for these subtypes of HPV but
rather indicative or reactivity to high-risk HPV E7 protein.
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Figure 2: Survival data of patients diﬀerentiated by anti-E7 trend.
The percent survival in each group following treatment is shown.
Positive for anti-E7 with increasing trend n = 4, positive for antiE7 with decreasing trend n = 19, negative for anti-E7 n = 25. Two
of four patients suﬀered recurrence, and all four patients suﬀered
mortality in the positive for anti-E7 with increasing trend group
by day 2035.

The study was reviewed and approved by the Institutional
Review Board at the University of Louisville (IRB# 08.0388,
15.0582) in compliance with the Declaration of Helsinki.
De-identiﬁed patient sera and clinical information were
obtained from the Clinical Trials Oﬃce Biorepository of
the Brown Cancer Center. Blood was drawn for serum analysis prior to treatment and every 3 months thereafter for 2
years. All serum specimens were obtained by collecting
blood into nonadditive vacutainers, processed by centrifugation after a 30-minute clot, aliquoted, and stored at 4°C until
analyzed.
Human E7 oncoprotein was created from a viral plasmid
(pQE30) in bacterial cell culture from the manufacturer
(Qiagen). The production of E7 oncoprotein was conﬁrmed
via gel electrophoresis and Western Blot. This same process
of E7 antigen production is described in more detail in our
previous manuscript [18]. The ELISA 96 plates (Immulon
2HB) were purchased from the manufacturer (Thermo
Sci). The ELISA tray was coated with E7 oncoprotein at
1:200 ratio with PBS for 1 hour and washed with ×3. Patient
serum at a 1:50 ratio with PBS was added to the ELISA tray
overnight. In the morning, the tray was washed ×3. Secondary mouse anti-human antibodies with alkaline phosphatase
conjugate (Sigma) were added at a 1:2000 ratio for 1 hour
and then washed with ×3. The signal was developed in the
ELISA tray by adding alkaline phosphatase per ELISA manufacturer instructions. The ELISA assays were then read via
Synergy HT (BioTek) at time intervals 30, 50, and 70
minutes. 50 minutes was used as the reporting data as it provided the clearest signal diﬀerentiation between test and
controls.
HPV-associated HNC patients were identiﬁed with p16
immunohistochemistry. All patients had cancers of the oropharynx with exception of patients 881 and 891. Patient 881
had a cancer of the larynx, and patient 891 had cancer of the
oral tongue. Anti-E7 positive patients were identiﬁed with
the standard ELISA cutoﬀ procedure: at least one visit where
the mean ELISA value was more than the mean of the negative control value +3 standard deviations (.545 for HPV-16
anti-E7 and .423 for HPV-18 anti-E7) which was established
in our p16 negative patients (750, 865, 872, and 1002). If the
patient did not meet this criterion, they were classiﬁed as
negative. Increasing trends were identiﬁed as at least 1
increasing trend line throughout the study period for highrisk anti-E7. Decreasing trending patients were deﬁned as
having no increasing trend and at least 1 decreasing trend
for high-risk anti-E7.
The data was analyzed utilizing the Microsoft Excel,
Prism, and MedCalc statistical software. The analysis of signiﬁcance was done via FISHER’s exact testing of contingency tables as the cohort was too small for a chi-square
analysis to be accurate. For contingency tables larger than
2 × 2, a Freeman-Halton extension was added to the FISHER’s exact test.

4

Journal of Oncology
Patient 619
HPV-16 anti-E7 ELISA value

HPV-16 anti-E7 ELISA value

Patient 610
0.8
0.6
0.4
0.2
0.0
0

1

2
3
4
Visit number

1.0
0.9
0.8
0.7
0.6
0.5
0

5

1.0
0.9
0.8
0.7
0

2
4
Visit number

4
6
Visit number

8

Patient 864

1.1

HPV-16 anti-E7 ELISA value

HPV-16 anti-E7 ELISA value

Patient 625

2

6

0.80
0.75
0.70
0.65
0.60
0.55
0

1 2 3
Visit number

4

Figure 3: HPV-16 anti-E7 ELISA trends in patients with increasing ELISA values. All patients suﬀered mortality following treatment, and
patients 610 and 625 suﬀered relapse following treatment. Note that HPV-16 was used to generate the E7 antigen but is not speciﬁc for this
subtype of HPV but rather indicative or reactivity to high-risk HPV E7 protein.

3. Results
Of the 48 patients in this study, our ELISA results indicate
that 45.8% are positive for high-risk anti-E7 at one or more
collection time points during the study period with positivity
being deﬁned as +3 standard deviations above the mean of
the p16 negative patients ELISA values. Of the 43 patients
available for follow-up, 56% were aged less than 60, 86%
were male, 95% were white, and 5% were African American.
The majority (91%) of patients were stage 3 or 4 at diagnosis.
The demographic and clinical characteristics of the patients
can be seen in supplementary table 1. Treatments underwent
by patients primarily were comprised of surgery followed by
immunotherapy, chemotherapy, and radiation. Speciﬁc
treatments chosen for each patient can be seen in
supplementary table 2. Eight patients had relapse of cancer
with metastasis to various sites including the lungs,
pericardium, lymph nodes, brain, bone, and liver. Nine
patients suﬀered mortality, and 8 patients suﬀered cancer
recurrence. The patients suﬀering recurrence and mortality
are shown and separated by HPV anti-E7 trend status in
supplementary table 3. Interestingly, two of the four
patients included in this study without p16 positivity
(patients 750, 865, 872, and 1002) had cancer recurrence
and 1 of 4 had cancer-associated mortality. Three of four
of these patients had negative anti-E7 values as predicted
by the lack of high-risk HPV infection.
E7 oncoprotein positivity at the ﬁrst visit was not useful
to predict recurrence and survival (p = 1). Patients who had

positive trending high-risk anti-E7 throughout the study
were more likely to have worse clinical outcome with relapse
of cancer or progression to mortality (p = :004). Of the 4
patients with an increasing anti-E7 trend, all had cancers
progressing to mortality and 2 had cancer that recurred. A
positive trending anti-E7 panel as a predictive test of recurrence or progression to mortality among p16+ HNC patients
confers a 36.36% (95% CI 10.93% to 69.21%) sensitivity,
100% speciﬁcity (95% CI 88.06% to 100%), positive predictive value of 100%, and negative predictive value of 83.3%
(72.60% to 86.62%).

4. Discussion
The presence of serum antibodies to E7 at the ﬁrst clinical
visit of HNSCC patients were measured for the ﬁrst time
recently and suggested that E7 may be a marker of cancer
recurrence [19]. Additionally, it has been reported that E6
and E7 positivity correlates with better survival but worse
tumor grade and stage [14]. However, no study to our
knowledge has yet identiﬁed oncoprotein titer variation
throughout the disease course to be useful for predicting
HPV HNC clinical outcome [19–22].
Our data did not demonstrate the same trend of E7
oncoprotein positivity at the ﬁrst visit to be useful to predict
recurrence and survival (p = 1). This is likely because our
study population was known HPV-associated HNC who
should have elevated E7 in the bloodstream before undergoing extensive treatment rather than the study population of
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all HNC patients used in previous studies where HPVassociated HNC confers better survival. For the HPVassociated HNC population, our data demonstrates that an
increasing anti-E7 trend throughout the course of treatment
predicts mortality (p = :0007) and recurrence or progression
to mortality (p = :004) with 100% speciﬁcity. The increasing
anti-E7 trend for patients experiencing relapse and mortality
is illustrated by the contingency tables (Tables 1 and 2), the
heat map (Figure 1), and relapsed patients 610 and 625
(Figures 2 and 3).
Our ELISA is not speciﬁc enough to distinguish between
subtypes of high-risk HPV accurately because of crossreactivity between other high-risk HPV E7 proteins present
in the sera due to sequence similarity. HPV-18 and HPV16 were used to produce E7 antigens because these are common subtypes of high-risk HPV; however, we have denoted
throughout the paper that the reactivity is against high-risk
HPV E7 instead of speciﬁc subtypes of HPV. Furthermore,
patients positive for both anti-E7 HPV 18 and anti-E7
HPV 16 do not necessarily indicate true positivity for both
antibodies because the antigens have over 40% sequence
similarity.
Although this data is not representative of speciﬁc subtypes of HPV E7 present in the sera, as a predictive test for
clinical relapse or progression to mortality trending highrisk anti-E7 among HPV+ HNC patients may have utility
as a speciﬁcity of 100% makes the test ideal for ruling in
the possibility of relapse and cancer mortality. This test
may allow increased disease activity to be identiﬁed, and
patients may beneﬁt from more aggressive treatment. The
sensitivity of 36.36% is relatively low and makes this a poor
screening test, especially for patients without high-risk
HPV-associated cancer.
This novel trend will be useful to future studies that
expand the sample size to introduce more biologic variability. Because of the ability of anti-E7 to predict clinical outcome and thus guide treatment, it should be considered as
a target for high-risk HPV-associated HNC patient monitoring. Previous data is limited regarding direct ELISA or E7 in
sera, although the clinical impact of a noninvasive test for
stratifying outcomes is large. The use of novel biomarkers
like E7 in conjunction with classical cancer staging techniques is critical to deliver high-quality tailored care. Further
research comparing the prognostic eﬃcacy of circulating E7
nucleic acid at sequential clinical visits with E7 antibodies
would be impactful. This data is important to further our
understanding of HPV serology, non-invasively monitor
persistent or occult tumors, and will help to create personalized cancer treatments in the future.

5. Conclusion
High-risk human papillomavirus-associated head and neck
cancer is an increasing issue with signiﬁcant clinical outcome heterogeneity. Trending anti-E7 via liquid biopsy is
strongly predictive of cancer recurrence or progression with
mortality (p = :004). Measuring E7 oncoprotein at consecutive clinical visits may be a highly speciﬁc way to rule in can-
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cer recurrence or fatal disease course, thus guiding head and
neck cancer therapy.

Data Availability
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